



OPEN ACCESS

EDITED AND REVIEWED BY
Bernd Rosenkranz,
Fundisa African Academy of Medicines
Development, South Africa

*CORRESPONDENCE

Wenqiang Li,
✉ gztylwq@foxmail.com,
✉ 405119923@qq.com
Xintao Zhang,
✉ zhangxintao@sina.com

[†]These authors have contributed equally to
this work

RECEIVED 21 March 2025

ACCEPTED 25 June 2025

PUBLISHED 17 September 2025

CITATION

Fan D, Liu H, Zhang Z, Su M, Yuan Z, Lin Y,
Yang S, Li W and Zhang X (2025) Correction:
Resveratrol and Angiogenin-2 combined with
PEGDA/TCS hydrogel for the targeted therapy
of hypoxic bone defects via activation of the
autophagy pathway.
Front. Pharmacol. 16:1597755.
doi: 10.3389/fphar.2025.1597755

COPYRIGHT

© 2025 Fan, Liu, Zhang, Su, Yuan, Lin, Yang, Li
and Zhang. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Correction: Resveratrol and Angiogenin-2 combined with PEGDA/TCS hydrogel for the targeted therapy of hypoxic bone defects via activation of the autophagy pathway

Dehui Fan^{1†}, Hengping Liu^{2†}, Zhenning Zhang¹, Meiyi Su¹,
Zhixian Yuan¹, Ying Lin¹, Shuquan Yang¹, Wenqiang Li^{3*} and
Xintao Zhang^{4*}

¹The Fifth Clinical College of Guangzhou University of Chinese Medicine Guangzhou, Guangdong
Second Traditional Chinese Medicine Hospital, Guangzhou, China, ²Beijing University of Chinese
Medicine Third Affiliated Hospital, Beijing, China, ³Engineering Technology Research Center for Sports
Assistive Devices of Guangdong, Guangzhou Sport University, Guangzhou, China, ⁴Department of Sports
Medicine and Rehabilitation, National and Local Joint Engineering, Research Center of Orthopaedic
Biomaterials, Peking University Shenzhen Hospital, Shenzhen, China

KEYWORDS

resveratrol, ANG2, autophagy, hypoxia condition, vascularization, bone defect

A Correction on

Resveratrol and Angiogenin-2 combined with PEGDA/TCS hydrogel for
the targeted therapy of hypoxic bone defects via activation of the
autophagy pathway

by Fan D, Liu H, Zhang Z, Su M, Yuan Z, Lin Y, Yang S, Li W and Zhang X (2021). *Front. Pharmacol.*
12:618724. doi: 10.3389/fphar.2021.618724


In the published article, there was an error in [Figures 3B, 4A,B](#) as published. Images
from different groups were stored in the same folder during image shooting, resulting in the
misuse of images. The corrected [Figures 3B, 4A,B](#) and their captions appear below.

In the published article, there was an error in [Figures 7A, 8](#) as published. The H&E, Masson,
OCN and CD31 staining images of the animal tissue sections in [Figures 7, 8](#) overlap with those
used in our previous published study. This occurred because the animal experiments for both
research projects were conducted concurrently, leading to inadvertent misplacement of data
files. The corrected [Figures 7A, 8](#) and their captions appear below.

The original article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been
generated by Frontiers with the support of artificial intelligence and reasonable efforts
have been made to ensure accuracy, including review by the authors wherever possible. If
you identify any issues, please contact us.



Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

